BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Down 10.7% in December

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 17,290,000 shares, a decline of 10.7% from the November 30th total of 19,360,000 shares. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is presently 8.7 days.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Counterweight Ventures LLC lifted its stake in BioCryst Pharmaceuticals by 591.7% in the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company's stock worth $710,000 after acquiring an additional 79,884 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock valued at $2,274,000 after buying an additional 86,571 shares in the last quarter. XTX Topco Ltd increased its holdings in BioCryst Pharmaceuticals by 299.0% in the second quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company's stock worth $970,000 after buying an additional 117,607 shares during the last quarter. Seven Eight Capital LP lifted its stake in shares of BioCryst Pharmaceuticals by 1,407.1% in the 2nd quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company's stock valued at $1,048,000 after purchasing an additional 158,358 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in shares of BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock worth $16,444,000 after buying an additional 84,102 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded down $0.01 on Tuesday, hitting $7.52. 1,513,767 shares of the company were exchanged, compared to its average volume of 2,813,235. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.88. The firm has a market capitalization of $1.56 billion, a P/E ratio of -12.33 and a beta of 1.79. The company's 50 day moving average price is $7.64 and its 200-day moving average price is $7.49.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same quarter in the prior year, the firm earned ($0.19) EPS. The firm's revenue was up 35.1% compared to the same quarter last year. As a group, equities analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

Analyst Ratings Changes

BCRX has been the topic of a number of research reports. Barclays boosted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. Royal Bank of Canada reissued an "outperform" rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Needham & Company LLC restated a "buy" rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.